5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment

Author(s): Gerard Rosse, Herve Schaffhauser

Journal Name: Current Topics in Medicinal Chemistry

Volume 10 , Issue 2 , 2010

Become EABM
Become Reviewer
Call for Editor


Cognitive impairment (CI) has been recognized as a core feature of Alzheimers disease (AD) and schizophrenia. The 5-HT6 receptor is an attractive target for the development of cognitive enhancers due to its unique localization and pharmacology. 5-HT6 receptor antagonists have been shown to modulate multiple neurotransmitter systems and therefore enhance cognition in preclinical studies. This premise translated into the clinical efficacy of the 5- HT6 receptor antagonist SB-742457 in mild-to-moderate AD patients. Advances in the understanding of the structureactivity- relationship, the design of novel 5-HT6 receptor ligands and their potential application for the treatment of CI are reviewed.

Keywords: Serotonin, G-Protein coupled receptor, medicinal chemistry, chemical biology, drug design, Alzheimer's disease, schizophrenia, neurological disorders

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [207 - 221]
Pages: 15
DOI: 10.2174/156802610790411036
Price: $65

Article Metrics

PDF: 46